Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation - Top-Institutions - DentalSpire

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

  • By

  • Kristina Maas-Bauer

  • Thomas Meyer

  • Mehtap Yücel

  • Maria Garofalaki

  • Stefanie Koßmann

  • Francesca Biavasco

  • Memnon Lysandrou

  • Miguel Waterhouse

  • Tobias Feuchtinger

  • Dietmar Pfeifer

  • Florian Ingelfinger

  • Tobias Wertheimer

  • Justus Duyster

  • Jae Sook Ahn

  • Robert J. Soiffer

  • Jürgen Finke

  • Ralph Wäsch

  • Alexandros Spyridonidis

  • Dennis Dong Hwan Kim

  • Claudia Wehr

  • Robert Zeiser

  • April 3, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology
    • Hematopoietic Cell Transplantation
    • Leukemia Genomics

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology/Oncology
    • Stem Cell Transplantation
    • Molecular Hematology

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology/Oncology
    • Stem Cell Transplantation
    • Cancer Genomics

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology/Oncology
    • Stem Cell Transplantation
    • Genomic Medicine

  • #5

    University of Washington School of Medicine
    University of Washington School of Medicine

    Seattle, WA

    Key Differentiators

    • Hematology
    • Transplantation Medicine
    • Molecular Oncology

Original Source(s)

Mutational landscape changes of AML in patients relapsing after allogeneic hematopoietic cell transplantation

  • by Kristina Maas-Bauer, Thomas Meyer, Mehtap Yücel, Maria Garofalaki, Stefanie Koßmann, Francesca Biavasco, Memnon Lysandrou, Miguel Waterhouse, Tobias Feuchtinger, Dietmar Pfeifer, Florian Ingelfinger, Tobias Wertheimer, Justus Duyster, Jae Sook Ahn, Robert J. Soiffer, Jürgen Finke, Ralph Wäsch, Alexandros Spyridonidis, Dennis Dong Hwan Kim, Claudia Wehr, Robert Zeiser

  • April 3, 2026

Related Content

PRDM1-mediated epigenetic and transcriptional repression mechanisms: a key hub in immune differentiation, tumor progression, and inflammatory responses

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report

Radiomics and deep learning in upper tract urothelial carcinoma: advancing preoperative risk stratification and clinical decision-making